Short Summary
CISCO SYSTEMS, INC. failed to overcome obviousness challenges against InfoExpress Inc.'s network security patent (8117645) before the PTAB. The Board denied institution because the petitioner could not demonstrate that prior art teachings sufficiently suggested specific auditing limitations in the claims.
Detailed Summary
The Patent Trial and Appeal Board denied institution of IPR2024-00678, finding that CISCO SYSTEMS, INC. failed to establish a reasonable likelihood of prevailing on grounds of obviousness (35 U.S.C. § 103). The claims at issue (1, 2, 5, and 6) were challenged over prior art references Krantz and Herrmann. Specifically regarding the Krantz ground, the Board accepted the Patent Owner's argument that the claim limitations for authentication and auditing are distinct and not taught by Krantz. Although a judge dissented on the second ground (Krantz/Herrmann), the majority ruled against institution based on insufficient teaching or suggestion of 'formulating an audit request.'
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in CISCO SYSTEMS, INC. et al. vs InfoExpress Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Amazon.com, Inc. et al.vsVirtaMove, Corp.
Amazon has filed an IPR petition seeking cancellation of 11 claims of VirtaMove’s 7,519,814 patent covering container virtualization. The petition argues obviousness over prior‑art systems such as Osman, Tucker, Bandhole and Gélinas and asserts no discretionary denial grounds.
Apple Inc.vs--
Apple moved to terminate IPR2025-00600 after a reexamination cancelled all claims of the 10,698,989 patent. The Board granted the motion, ending the proceeding before institution.
Google LLCvsSecure Communication Technologies, LLC
Google successfully challenged Secure Communication Technologies’ patent covering proximity‑based data exchange, resulting in a Final Written Decision that all fifteen challenged claims are unpatentable.
AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.
Azurity has filed an IPR petition seeking cancellation of all 23 claims of Helsinn’s U.S. Patent 9,943,515 covering netupitant‑based anti‑emetic regimens, arguing the claims are obvious over prior‑art combinations and lack secondary considerations.
Taiwan Semiconductor Manufacturing Company, Ltd. et al.vsMarlin Semiconductor Ltd. et al.
TSMC and Apple attempted to overturn USPTO denials of institution for Marlin Semiconductor patents, but the Board denied their Director Review requests, leaving the institution decisions intact.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.